This work paves the way that the TGFaL3-Peptide conjugates produced in this work could be used for targeting the treatment of EGFR-expressing cancer cells (Figure 9), and will build the ground for in vivo investigations of these novel conjugates. This evidence concerns the gene EGFR and cancer.